Ken Griffin Spring Works Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$32.04 - $42.76 $211,464 - $282,216	-6,600 Reduced 16.54%	33,300 $1.07 Million
Q2 2024 Aug 14, 2024	BUY	$36.06 - $47.62 $1.1 Million - $1.45 Million	30,500 Added 324.47%	39,900 $1.5 Million
Q1 2024 May 15, 2024	SELL	$36.5 - $52.5 $1.05 Million - $1.51 Million	-28,700 Reduced 75.33%	9,400 $462,000
Q4 2023 Feb 14, 2024	BUY	$18.94 - $37.24 $632,596 - $1.24 Million	33,400 Added 710.64%	38,100 $1.39 Million
Q3 2023 Nov 14, 2023	SELL	$23.12 - $31.38 $104,040 - $141,210	-4,500 Reduced 48.91%	4,700 $108,000
Q2 2023 Aug 14, 2023	BUY	$23.15 - $32.71 $113,435 - $160,279	4,900 Added 113.95%	9,200 $241,000
Q4 2022 Feb 14, 2023	SELL	$21.73 - $28.72 $591,056 - $781,184	-27,200 Reduced 86.35%	4,300 $111,000
Q3 2022 Nov 14, 2022	SELL	$24.1 - $39.66 $67,480 - $111,047	-2,800 Reduced 8.16%	31,500 $899,000

238

69.8M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.57B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.